Compass Therapeutics Inc (CMPX)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Existing outlays were on the rise at the Compass Therapeutics Inc in the first quarter of 2023
Compass Therapeutics Inc announced first quarter of 2023 operating shortfall of $-9.711 million
Published 2023-05-05T21:29:52+00:00
Goran Soko / CSIMarket.com Contributer
![Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons")
The investors have not expected some changes at the revenue throughout the the January to March 31 2023 reporting cycle at the company. But, they monitor CMPXs' operating shortfall which came in at $-9.711 million, during the matching time. The brilliant effort to interpret the financial interval ending first quarter of 2023 outcome, in the current level of the business. Now, it's straight forward to correlate the operating shortfall of the first quarter of 2022, which came in $-7.182 million.
The management is out for various business strategies, in attempt to ensure business. Meanwhile the deficit, which the company has endured all along the emerging stage, has swelled to $-7.837 million, from $-7.162 million, from the first quarter of 2022.
Compass Therapeutics Inc is expected to report next financial results on July 31, 2023.